公开(公告)号：US08926972B2

公开(公告)日：2015-01-06

申请号：US12727188

申请日：2010-03-18

Applicant: Joe Zhou ,  Jianyang Zhao ,  Jiuru Sun ,  Jun Wang ,  Shaoxiong Wang ,  Xinxing Ma ,  Jun Lin

Inventor： Joe Zhou ,  Jianyang Zhao ,  Jiuru Sun ,  Jun Wang ,  Shaoxiong Wang ,  Xinxing Ma ,  Jun Lin

IPC: A61K38/18 ,  C07K14/71 ,  A61K38/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K2319/30

Abstract: The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.

Abstract translation: 本公开提供了一种新的抗血管生成融合蛋白。 本发明将嵌合血管内皮细胞生长因子（VEGF）受体或其片段与多聚化成分组合，其与人VEGF和胎盘生长因子（PIGF）具有优异的结合能力。 融合蛋白具有改善的稳定性，延长的半衰期和与VEGF形成多价相互作用的能力，并且可用于抗血管生成，治疗VEGF相关疾病和抑制肿瘤生长。

公开(公告)号：US20100331250A1

公开(公告)日：2010-12-30

申请号：US12727188

申请日：2010-03-18

Applicant: Joe ZHOU ,  Jianyang Zhao ,  Jiuru Sun ,  Jun Wang ,  Shaoxiong Wang ,  Xinxing Ma ,  Jun Lin

Inventor： Joe ZHOU ,  Jianyang Zhao ,  Jiuru Sun ,  Jun Wang ,  Shaoxiong Wang ,  Xinxing Ma ,  Jun Lin

IPC: A61K38/18 ,  C12P21/06 ,  C12N5/10 ,  C12N1/19 ,  C12N15/63 ,  C07K14/705 ,  C07K16/22 ,  C07H21/04

CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K2319/30

Abstract: The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.

Abstract translation: 本公开提供了一种新的抗血管生成融合蛋白。 本发明将嵌合血管内皮细胞生长因子（VEGF）受体或其片段与多聚化成分组合，其与人VEGF和胎盘生长因子（PIGF）具有优异的结合能力。 融合蛋白具有改善的稳定性，延长的半衰期和与VEGF形成多价相互作用的能力，并且可用于抗血管生成，治疗VEGF相关疾病和抑制肿瘤生长。